Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma

British Journal of Haematology

Volumn 143, Issue 5, 2008, Pages 672-680

  Nagai, Hirokazu ^a   Yano, Takahiro ^a   Watanabe, Tomoyuki ^a,b   Uike, Naokuni ^a   Okamura, Seiichi ^c   Hanada, Shuichi ^d   Kawano, Fumio ^a   Sunami, Kazutaka ^a   Inoue, Nobumasa ^a   Sawamura, Morio ^a   Nishiura, Tetsuo ^a   Hotta, Tomomitsu ^a   Horibe, Keizo ^a  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b AICHI GAKUIN UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KAGOSHIMA MEDICAL CENTER   (Japan)

Author keywords

Clinical practice; Diffuse large B cell lymphoma; Rituximab follicular lymphoma

Indexed keywords

RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 55949136920     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07390.x     Document Type: Article

References (19)

1. Carbone, P.P., Kaplan, H.S., Musshoff, K., Smithers, D.W. Tubiana, M. (1971) Report of the Committee on Hodgkin's disease staging classification. Cancer Research, 31, 1860 1861.
2. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235 242.
3. Czuczman, M.S., Grillo-López, A.J., White, C.A., Saleh, M., Gordon, L., LoBuglio, A.F., Jonas, C., Klippenstein, D., Dallaire, B. Varns, C. (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. Journal of Clinical Oncology, 17, 268 276.
4. Czuczman, M.S., Weaver, R., Alkuzweny, B., Berlfein, J. Grillo-López, A.J. (2004) Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. Journal of Clinical Oncology, 22, 4711 4716.
5. Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Hänel, A., Metzner, B., Pott, C., Hartmann, F., Rothmann, F., Rohrberg, R., Böck, H.P., Wandt, H., Unterhalt, M., Hiddemann, W. German Low-Grade Lymphoma Study Group 2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 104, 3064 3071.
6. Habermann, T.M., Weller, E.A., Morrison, V.A., Gascoyne, R.D., Cassileth, P.A., Cohn, J.B., Dakhil, S.R., Woda, B., Fisher, R.I., Peterson, B.A. Horning, S.J. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 24, 3121 3127.
7. Herold, M., Haas, A., Srock, S., Neser, S., Al-Ali, K.H., Neubauer, A., Dölken, G., Naumann, R., Knauf, W., Freund, M., Rohrberg, R., Höffken, K., Franke, A., Ittel, T., Kettner, E., Haak, U., Mey, U., Klinkenstein, C., Assmann, M., von Grünhagen, U. East German Study Group Hematology and Oncology Study 2007) Rituximab added to first-line mitoxantrone. Chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. Journal of Clinical Oncology, 25, 1986 1992.
8. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.E., Freund, M., Wörmann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trümper, L., Aldaoud, A., Parwaresch, R. Unterhalt, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, 3725 3732.
9. Lenz, G., Dreyling, M., Hoster, E., Wörmann, B., Dührsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., Martin, S., Heidemann, E., Aldaoud, A., Parwaresch, R., Hasford, J., Unterhalt, M. Hiddemann, W. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and predonisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Journal of Clinical Oncology, 23, 1984 1992.
10. MacLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 2825 2833.
11. Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E., Catalano, J., Solal-Celigny, P., Offner, F., Walewski, J., Raposo, J., Jack, A. Smith, P. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, 1417 1423.
12. van Oers, M.H., Klasa, R., Marcus, R.E., Wolf, M., Kimby, E., Gascoyne, R.D., Jack, A., Van't Veer, M., Vranovsky, A., Holte, H., van Glabbeke, M., Teodorovic, I., Rozewicz, C. Hagenbeek, A. (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood, 108, 3295 3301.
13. Pfreundschuh, M., Trümper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., López-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E., Loeffler, M. MabThera International Trial Group 2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInt) Group. Lancet oncology, 7, 379 391.
14. Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., Reiser, M., Nickenig, C., Clemens, M., Peter, N., Bokemeyer, C., Eimermacher, H., Ho, A., Hoffmann, M., Mertelsmann, R., Trümper, L., Balleisen, L., Liersch, R., Metzner, B., Hartmann, F., Glass, B., Poeschel, V., Schmitz, N., Ruebe, C., Feller, A.C., Loeffler, M. German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) 2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncology, 9, 105 116.
15. Rivas-Vera, S., Baez, E., Sobrevilla-Calvo, P., Baltazer, S., Tripp, F., Vela, J., Garces, O., Aguilar, L., Ignacio, G., Duque, J., Rodriguez, P. Reyes, G. (2005) Is first line single agent rituximab the best treatment for indolent non-Hodgkin's lymphoma? Update of a multicentric study comparing rituximab vs CNOP vs rituximab plus CNOP. Blood, 106 (Suppl. 1 684.
16. Schulz, H., Bohlius, J.F., Trelle, S., Skoetz, N., Reiser, M., Kober, T., Schwarzer, G., Herold, M., Dreyling, M., Hallek, M. Engert, A. (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. Journal of the National Cancer Institute, 99, 706 714.
17. Sehn, LH, Donaldson, J, Chhanabhai, M., Fitzgerald, C., Gill, K., Klasa, R., MacPherson, N., O'Reilly, S., Spinelli, J.J., Sutherland, J., Wilson, K.S., Gascoyne, R.D. Connors, J.M. (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. Journal of Clinical Oncology, 23, 5027 5033.
18. Sehn, L.H., Berry, B., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K.J., Shenkier, T., Sutherland, J., Gascoyne, R.D. Connors, J.M. (2007) The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109, 1857 1861.
19. The International Non-Hodgkin's Lymphoma Prognostic Factors Project 1993) A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine, 329, 987 994.